A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2023-04-18
Adverse events
Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 34); relationship: not assessed
Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 119); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-07 (study day 197); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-25 (study day 336); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 338); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-06-10 (study day 413); relationship: not assessed
Grade 4 Thrombocytopenia — outcome: UNKNOWN; onset 2024-06-29 (study day 432); relationship: N; serious criteria: life-threatening
Data queries
No data queries.